Spruce Biosciences, Inc. (SPRB), a late-stage biopharmaceutical company, priced its previously announced public offering of 1.15 million shares at $50 per share and pre-funded warrants to purchase 50,000 shares of common stock at a purchase price of $49.99 per share. The gross proceeds to Spruce Biosciences from the offering are expected to be $60 million.
Spruce Biosciences has granted the underwriters a 30-day option to purchase up to an additional 0.18 million shares.
Leerink Partners, Guggenheim Securities, and Oppenheimer & Co. are acting as joint book-running managers.
The offering is expected to close on April 22, 2026, subject to customary closing conditions.
Spruce focuses on therapies for neurological disorders and develops TA-ERT, an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B, and Tildacerfont for the treatment of Congenital Adrenal Hyperplasia (CAH).
SPRB has traded between $7.00 and $838.12. The stock closed Monday's trade at $69.89, down 0.58%.
In the pre-market, SPRB is down 21.95% at $54.55.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.